Sitagliptin, a highly selective DPP‐4 inhibitor, as an available anti‐diabetic agent, is generally used in clinical treatment of type 2 diabetes,19, 31 without common adverse effects, relevant drug interactions and cardiovascular risk.14, 22, 23. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.